All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation
Peptide-drug conjugates aim to transport inactive anti-tumor agent to malignant cells, which is then cleaved to an active cytotoxic drug. Such approach minimizes effect on healthy cells and leads to reduced adverse side effects. The peptide-drug conjugates consist of the tumor-homing peptide, the cytotoxic agent, and the biodegradable connecting linker.